Dry Eye

The second pivotal phase 3 data on NOV03 (perfluorohexyloctane) show that NOV30 consistently met primary endpoints for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Catch up on what to expect from Lumenis.

How one OD incorporated full-service dry eye treatment.

The ones you should seek out—and avoid.

BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.

The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Staying up-to-date on all things ocular is imperative in ocular surface disease.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

Marc R. Bloomenstein, OD, FAAO, gives an overview of the SAHARA study.

Selina McGee, OD, FAAO, founder and owner of BeSpoke Vision in Edmond, Oklahoma, shares key takeaways from her discussion, "Pro- and Anti-Inflammatory Cytokine Levels in Tears of Dry Eye Subjects,“ which she presented during the 2022 American Academy of Optometry meeting in San Diego.

Pinakin Davey, PhD, OD, FAAO, gives key highlights from his AAOpt 2022 presentation, "Management of digital eye strain: comprehensive strategy and nutritional approach."

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Nidhi Rana, OD, discusses key highlights from her AAOpt 2022 presentation on pediatric red eye.

Derek Cunningham, OD, FAAO, gives key takeaways from his AAOpt 2022 discussion, "Back to the basics: The importance of treating inflammation AND obstruction for dry eye."

Jeff Nau, PhD, president and CEO of Oyster Point Pharma shares an update on the company's Tyrvaya product.

When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.

Modern technology enables early detection, individualized solutions.

Preservative-free eye drops offer benefits for ocular health.

Katherine M. Mastrota, OD, FAAO, advises on how to diagnosis this condition and not fall prey to a “knee-jerk” dry eye diagnosis.

When oral acne treatments lead to ocular surface disease, the solution lies in office-based therapies.

Janelle Davison, OD, shares highlights from her VEW 2022 presentation, "Intersection of dry eye and beauty: design, build and brand a profitable dry eye spa."

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.

FDA-approved steroid offers short-term relief for ocular surface inflammation.